SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
JPMorgan U.S. Equity Fund Class I (JUESX) trades at a trailing P/E of 1.6. Trailing earnings yield is 60.98%. PEG 0.05 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (1.6); PEG ≤ 1.0 — Peter Lynch undervalued (0.05); earnings yield beats bond yields (60.98%).
- PEG Ratio 0.05 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 60.98% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 90/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — JUESX
Valuation Multiples
P/E (TTM)1.6
Forward P/EN/A
PEG Ratio0.05
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.54
EV/EBITDA0.0
Per Share Data
EPS (TTM)$16.23
Book Value / Share$0.00
Revenue / Share$49.61
FCF / Share$0.00
Yields & Fair Value
Earnings Yield60.98%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$5.29 |
$91.97B |
$20.08B |
21.8% |
| 2015 |
$6.00 |
$89.2B |
$22.65B |
25.4% |
| 2016 |
$6.19 |
$91.21B |
$22.83B |
25% |
| 2017 |
$6.31 |
$94.75B |
$22.57B |
23.8% |
| 2018 |
$9.00 |
$103.74B |
$30.71B |
29.6% |
| 2019 |
$10.72 |
$110.13B |
$34.64B |
31.5% |
| 2020 |
$8.88 |
$102.47B |
$27.41B |
26.7% |
| 2021 |
$15.36 |
$130.9B |
$46.5B |
35.5% |
| 2022 |
$12.08 |
$122.3B |
$35.89B |
29.3% |
| 2023 |
$16.23 |
$146.01B |
$47.76B |
32.7% |
